Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

OB GYN new masthead 1

OB/GYN Clinical Alert – September 1, 2016

September 1, 2016

View Archives Issues

  • Is an Even Safer Combined Oral Contraceptive Pill Available?

    ABSTRACT & COMMENTARY: New study has many advantages, including ascertainment of important confounding variables.

  • Genetic Testing: Who Should Be Tested and What Should They Be Tested For?

    Genetic testing has changed rapidly over the past three years, so to prevent cancer, it is critical that obstetricians-gynecologists take a complete family history, identify women at risk, and make appropriate referrals for genetic counseling with potential testing to prevent cancer.

  • Oligohydramnios: How to Best Diagnose It and What It Really Means

    A multicenter randomized, clinical trial involving large numbers of patients has shown that using the maximal vertical pocket instead of the amniotic fluid index to detect oligohydramnios more than halves the amount of inductions for the diagnosis of oligohydramnios without affecting the overall outcome.

  • PCOS and Hormonal Contraception: A Tale of Two Syndromes?

    Emerging evidence supports that two metabolic phenotypes exist among women with PCOS. For metabolically healthy PCOS patients, managing menstrual symptoms, anovulation and androgen excess with COCs provides a simple and well-tolerated treatment regimen. In contrast, PCOS patients with metabolic syndrome are at high risk for type 2 diabetes, and COC use may contribute to hyperinsulinemia, adverse lipid changes, and endothelial changes associated with adverse cardiovascular risk. The use of a levonorgestrel intrauterine device combined with spironolactone (to manage hyperandrogenism) and metformin (to manage hyperinsulinism) may offer advantages to metabolically unhealthy PCOS patients.